Megan Moynahan
About Megan Moynahan
Role(s) / Profession(s)
- Government Employee
Organization
- U.S. Food and Drug Administration - FDA
Work Location(s)
- United States
Language(s)
Megan's Communities
Recent Contributions
-

Megan Moynahan replied to "Malaria RDT Expert Panel SESSION 3: Assessment, Procurement and Financing" in the Malaria Treatment & Prevention community.
Here is Dr Poole's response to the second question, What are challenges to successful implementation? FDA Response: Some challenges to successful implementation are: 1) inadequate laboratory training of users 2) tests developed in US were not evaluated under conditions present in developing countries. e.g., extreme temperatures, power outages, contamination in ...
-

Megan Moynahan replied to "Malaria RDT Expert Panel SESSION 3: Assessment, Procurement and Financing" in the Malaria Treatment & Prevention community.
Here's Dr Poole's reply to the first question: In order for a malaria RDT to be distributed in the U.S. premarket clearance is required. Malaria RDTs have been classified under 21CFR 866.3402 as "Plasmodium species antigen detection assays", Class II devices. A description of these devices can be found in ...
-

Megan Moynahan replied to "Malaria RDT Expert Panel SESSION 3: Assessment, Procurement and Financing" in the Malaria Treatment & Prevention community.
I'd like to provide FDA's comment to the first question, but first I'd like to introduce the subject matter expert who provided the information to me: Freddie M. Poole, MS, is the Associate Director of the Division of Microbiology Devices in the Office of In Vitro Diagnostic Devices, and supervises ...
Recent Recommendations
- None at this time.
